Holen Sie sich die Stockscreener-App
4.95
2.70%
0.13
Vorhandelsmarkt:
4.94
-0.010
-0.20%
Evolus Inc Aktie (EOLS) Neueste Nachrichten
How A New Price Target Is Shaping The Evolus (EOLS) Story - Yahoo Finance
Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at BTIG Research - MarketBeat
EOLS: BTIG Lowers Price Target While Maintaining Buy Rating | EO - GuruFocus
Understanding Momentum Shifts in (EOLS) - Stock Traders Daily
BTIG lowers Evolus stock price target to $13 on aesthetic market decline - Investing.com Nigeria
Evolus projects robust 2025 growth with upcoming product launches - MSN
Panic Selling: Should you avoid Evolus Inc stock right nowEarnings Performance Report & Capital Efficient Trade Techniques - baoquankhu1.vn
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop - 富途牛牛
VIX Spike: Is Evolus Inc undervalued by DCF analysis2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00 | - GuruFocus
Stifel lowers Evolus stock price target to $17 on tempered growth outlook - Investing.com Australia
Stifel lowers Evolus stock price target to $17 on tempered growth outlook By Investing.com - Investing.com South Africa
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (EOLS) Movement - Stock Traders Daily
Evolus reports 15% Q4 growth, projects 2026 profitability By Investing.com - Investing.com Nigeria
Evolus sees FY26 revenue $327M-$337M, consensus $351.66M - TipRanks
Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: Unpacking a 222% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
EOLS: HC Wainwright & Co. Reiterates Buy Rating with $20 Price T - GuruFocus
Evolus' (EOLS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Evolus (EOLS) Projects Strong Revenue Growth Through 2028 - GuruFocus
EOLS Projects Strong Revenue Growth with Key Product Line - GuruFocus
Evolus (EOLS) Achieves Sixth Year of Double-Digit Growth in 2025 - GuruFocus
EOLS Projects Optimistic Growth with Strategic Market Expansion - GuruFocus
Evolus outlook FY sales USD 327-337 million - marketscreener.com
Evolus reports 15% Q4 growth, projects 2026 profitability - Investing.com
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue - Business Wire
How Evolus Inc. stock valuations compare to rivalsMarket Growth Review & Stock Timing and Entry Methods - Улправда
Does Evolus Inc. stock trade at a discount to peersChart Signals & Reliable Breakout Forecasts - Улправда
Why Evolus Inc. stock is favored by top institutions2025 Performance Recap & Expert Curated Trade Setup Alerts - Улправда
Can Evolus Inc. stock deliver strong Q4 earningsSwing Trading Ideas & Small Budget Portfolio Growth - Улправда
Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value - simplywall.st
Mizuho cuts Evolus (EOLS) estimates for Jeuveau/Evolysse on waning consumer sentiment and inflationary pressure on elective aesthetics - MSN
Will Evolus Inc. (EVL) stock benefit from sector leadershipRisk Mitigation Techniques & Low Entry Cost Investments - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Discipline and Rules-Based Execution in EOLS Response - Stock Traders Daily
Avelar Rui, Evolus officer, sells $16k in EOLS stock By Investing.com - Investing.com India
Evolus CEO Moatazedi sells $75k in shares By Investing.com - Investing.com Australia
Evolus CEO Moatazedi sells $75k in shares - Investing.com
Avelar Rui, Evolus officer, sells $16k in EOLS stock - Investing.com
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 10,539 Shares of Stock - MarketBeat
Rui Avelar Sells 2,261 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
Evolus, Inc. $EOLS Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Big Picture: Does Evolus Inc stock trade at a discount to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn
Evolus' (EOLS) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Needham Reiterates Evolus (EOLS) Hold Recommendation - Nasdaq
0.51%
9.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):